AML1–ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The transcription factor CCAAT/enhancer binding protein alpha, or C/EBPalpha, encoded by the CEBPA gene, is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and Cebpa knockout mice exhibit an early block in maturation. Dominant-negative mutations of CEBPA have been found in some patients with acute myeloid leukemia (AML), but not in AML with the t(8;21) translocation which gives rise to the fusion gene RUNX1-CBF2T1 (also known as AML1-ETO) encoding the AML1-ETO fusion protein. RUNX1-CBF2T1 positive-AML blasts had eight-fold lower CEBPA RNA levels and undetectable C/EBPalpha protein levels compared with other subgroups of AML patients. Conditional expression of RUNX1-CBF2T1 in U937 cells downregulated CEBPA mRNA, protein and DNA binding activity. AML1-ETO appears to suppress C/EBPalpha expression indirectly by inhibiting positive autoregulation of the CEBPA promoter. Conditional expression of C/EBPalpha in AML1-ETO-positive Kasumi-1 cells results in neutrophilic differentiation. We suggest that restoring C/EBPalpha expression will have therapeutic implications in RUNX1-CBF2T1-positive leukemias.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and abolishes C/EBP 𝛂 expression. 54”
From RUNX/AML and C/EBP factors regulate CD11a integrin expression in myeloid cells through overlapping regulatory elements. (2003) · cites this paper as [54]
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1×
“The U937T cell line in which U937 cells were stably transfected with the tetracycline transactivator (tTA) under the control of a tetracycline responsive elemen”
BackgroundEstablishment and characterization of a human histiocytic lymphoma cell line (U‐937)
Sundström, C., & Nilsson, K. (1976) · International Journal of Cancer · doi:10.1002/ijc.2910170504 · Cited by 2,407
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Luciferase reporter gene vectors for analysis of promoters and enhancers.
Nordeen, S. K. (1988) · PubMed · Cited by 994
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910
Self-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901 · cited 1×
“a the abnormalities were one del (9)(q22;q34); one t(6;9); one t(10;21)(p11;q22); one 8;one 14; and one complex aberrant karyotype.”
BackgroundSelf-citationMiyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872
Cited by
Items 301–400 of 462
Geest, C. R., Buitenhuis, M., Vellenga, E., & Coffer, P. J. (2009) · Haematologica · doi:10.3324/haematol.2008.000471 · Cited by 14
Investigation of CEBPA and CEBPA-AS Genes Expression in Acute Myeloid Leukemia.
Gholami, M., Bayat, S., Manoochehrabadi, S., Pashaiefar, H., Omrani, M. D., Jalaeikhoo, H., Yassaee, V. R., Ebrahimpour, M. R., Behjati, F., & Mirfakhraie, R. (2019) · Europe PMC (PubMed Central) · Cited by 13
Expression of different functional isoforms in haematopoiesis
Grech, G., Pollacco, J., Portelli, M., Sacco, K. A., Baldacchino, S., Grixti, J. M., & Saliba, C. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1477-7 · Cited by 17
“The proper AUG of the full-length protein is skipped due to the overlapping reading frames, and a downstream AUG codon is selected resulting in truncated transcription factors acting as dominant negative isoforms [39].”
BackgroundWertheim, G. B. W., Hexner, E. O., & Bagg, A. (2012) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-012-0009-0 · Cited by 18
“Interestingly, normal CEBPA expression is disrupted by the two core binding factor translocations that define the AML subcategories t(8;21) and inv(16)/t(16;16) [70, 71].”
BackgroundWeng, S., Matsuura, S., Mowery, C. T., Stoner, S. A., Lam, K., Ran, D., Davis, A. G., Lo, M.-C., & Zhang, D.-E. (2016) · Leukemia · doi:10.1038/leu.2016.167 · Cited by 14
Self-citationNakamae, I., Kato, J., Yokoyama, T., Ito, H., & Yoneda‐Kato, N. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007054 · Cited by 17
Derangement of transcription factor profiles during in vitro differentiation of HL60 and NB4 cells
Bjerregaard, M. D., Borregaard, N., & Cowland, J. B. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.07.019 · Cited by 17
“Chroosomal translocations involving Runx1 (also called AML1) 1], and mutations or deregulation of C/EBP [2–4] is freuently observed in acute myeloid leukemia (AML) patients.”
BackgroundZhang, J., Wilkinson, J. E., Gonit, M., Keck, R. W., Selman, S. H., & Ratnam, M. (2008) · The Prostate · doi:10.1002/pros.20779 · Cited by 13
Zhao, M. L., Duan, X.-F., Zhao, X.-Y., Zhang, B., Lu, Y., Liu, W., Cheng, J.-K., & Chen, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006552 · Cited by 13
“, and inhibition of its expression or function is also blocked by leukemogenesis-related genetic alterations such as t(8;21)-generated AML1-ETO”
BackgroundEl‐Sharkawi, D., Sproul, D., Allen, C. G., Feber, A., Wright, M., Hills, R. K., Linch, D. C., & Gale, R. E. (2017) · Haematologica · doi:10.3324/haematol.2017.173096 · Cited by 13
G ENETIC P ROFILE OF A CUTE M YELOID L EUKEMIA
Mecucci, C., Rosati, R., & Starza, R. L. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00060.x · Cited by 13
Granulocyte colony‐stimulating factor and leukemogenesis
de Figueiredo‐Pontes, L. L., Lima, R. S., & Rego, E. M. (2004) · Mediators of Inflammation · doi:10.1080/09511920410001713574 · Cited by 13
Fleenor, C. J., Higa, K. C., Weil, M. M., & DeGregori, J. V. (2015) · Radiation Research · doi:10.1667/rr14147.1 · Cited by 13
The microRNAs involved in human myeloid differentiation and myelogenous/myeloblastic leukemia
Wang, X., & Zhang, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00386.x · Cited by 11
“While C/EBP has critical roles in the differentiation of bipotential myeloid progenitors to granulocytes [78–80], it can down-regulate c-myc expression [81] and can be down-regulated by the formation of AML1-ETO fusion protein [82].”
BackgroundRUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML
Hyde, R. K., Liu, P., & Friedman, A. D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_17 · Cited by 13
Hasemann, M. S., Damgaard, I., Schuster, M. B., Theilgaard‐Mönch, K., Sørensen, A. B., Mršić, A., Krugers, T., Ylstra, B., Pedersen, F. S., Nerlov, C., et al. (2008) · Blood · doi:10.1182/blood-2007-06-097790 · Cited by 11
Biology of Hematopoietic Stem and Progenitor Cells
Manz, M. G., Akashi, K., & Weissman, I. L. (2003) · Wiley eBooks · doi:10.1002/9780470987070.ch8 · Cited by 15
Ferrari‐Amorotti, G., Mariani, S. A., Novi, C., Cattelani, S., Pecorari, L., Corradini, F., Soliera, A. R., Manzotti, G., Fragliasso, V., Zhang, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.128272 · Cited by 15
Juhl‐Christensen, C., Bomberg, M., Melsvik, D., Hokland, P., & Nyvold, C. G. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01117.x · Cited by 9
Towards a pathogenesis-oriented therapy of acute myeloid leukemia
Hiddemann, W., Spiekermann, K., Buske, C., Feuring‐Buske, M., Braess, J., Haferlach, T., Schoch, C., Kern, W., Schnittger, S., Berdel, W. E., et al. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.07.004 · Cited by 10
Self-citationFrom Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis
Mulet‐Lazaro, R., & Delwel, R. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000969 · Cited by 11
“One of such driver epimutations is the inactivation of the CEBPA +42 kb enhancer in AML with t(8;21), 294–296 stemming from the recruitment of HDACs and other repressors 306,307 by the RUNX1-ETO oncoprotein.”
BackgroundKing, Z., Desai, S. R., Frank, D. A., & Shastri, A. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101137 · Cited by 12
“RUNX1-ETO, an onco-fusion protein generated by t(8:21) induces leukemogenesis by directly repressing the transcription of TF C/EBP α thereby blocking the granulocyte differentiation and repressing tumor suppressor TF, p14 (ARF)[52,53].”
Proteomic approaches in myeloid leukemia
Kanaujiya, J. K., Lochab, S., Pal, P., Christopeit, M., Singh, S. M., Sanyal, S., Behre, G., & Trivedi, A. K. (2011) · Electrophoresis · doi:10.1002/elps.201000428 · Cited by 9
Self-citationHirai, H., Kamio, N., Huang, G., Matsusue, A., Ogino, S., Kimura, N., Satake, S., Ashihara, E., Imanishi, J., Tenen, D. G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054862 · Cited by 9
Self-citationShimokawa, T., Nunomura, S., Fujisawa, D., & Ra, C. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.09.004 · Cited by 10
CCAAT/enhancer binding protein α gene expression in Egyptian patients with acute myeloid leukemia
Kassem, N. M. A., Fahmy, A. E.-G., Eldesoky, M. A., Medhat, N., & Zawam, H. M. (2013) · Journal of the Egyptian National Cancer Institute · doi:10.1016/j.jnci.2013.02.002 · Cited by 8
Kagita, S., Uppalapati, S., Gundeti, S., & Digumarti, R. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv064 · Cited by 9
Molecular biology in acute leukemia
Camós, M., & Colomer, D. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0060-6 · Cited by 9
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells
Sun, Y., Wu, Y., Pang, G.-Z., Huang, J., Sheng, M., Xie, J., Chen, P., Wang, Y., Yin, D., Zhao, G., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02383-8 · Cited by 9
Optimizing homeostatic cell renewal in hierarchical tissues
Alvarado, C., Fider, N. A., Wearing, H. J., & Komarova, N. L. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005967 · Cited by 8
Krygier, A., Szmajda‐Krygier, D., Sałagacka-Kubiak, A., Jamroziak, K., Żebrowska-Nawrocka, M., & Balcerczak, E. (2020) · Medical Oncology · doi:10.1007/s12032-020-01436-z · Cited by 8
“It is specifically upregulated during a granulocytic differentiation, but downregulated during the monocytic pathway [34, 35].”
BackgroundResultThe telomere complex and the origin of the cancer stem cell
Torres-Montaner, A. (2021) · Biomarker Research · doi:10.1186/s40364-021-00339-z · Cited by 9
Nie, Y., Su, L., Li, W., & Gao, S. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103379 · Cited by 10
Wang, H., Luo, G., Hu, X., Xu, G., Wang, T., Liu, M., Qiu, X., Li, J., Fu, J., Feng, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37381-4 · Cited by 9
Kanellou, P., Georgakopoulos‐Soares, I., & Zaravinos, A. (2023) · Cancers · doi:10.3390/cancers15061795 · Cited by 8
“In concordance, AML cells expressing the RUNX1/RUNX1T1 fusion have been shown to be sensitive to the inbitition of the JAK-STAT pathway [48].”
BackgroundYan, M., Liu, M., Davis, A. G., Stoner, S. A., & Zhang, D. (2023) · Leukemia · doi:10.1038/s41375-023-02063-z · Cited by 7
Self-citationCEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment
Tien, F., & Hou, H. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03773-5 · Cited by 8
Fos, J., Pabst, T., Petkovic, V., Ratschiller, D., & Mueller, B. U. (2011) · Blood · doi:10.1182/blood-2010-11-320747 · Cited by 11
Self-citationKo, R. M., Kim, H., Wolff, L., & Klug, C. A. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.10.012 · Cited by 7
“Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.”
BackgroundSchoenherr, C., Wohlan, K., Dallmann, I., Pich, A., Hegermann, J., Ganser, A., Hilfiker‐Kleiner, D., Heidenreich, O. T., Scherr, M., & Eder, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225977 · Cited by 7
K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
Carnicer, M. J., Lasa, A., Buschbeck, M., Serrano, E., Carricondo, M., Brunet, S., Aventin, A. M., Sierra, J., Croce, L. D., & Nomdedeu, J. F. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0528-2 · Cited by 10
Fragliasso, V., Chiodo, Y., Ferrari‐Amorotti, G., Soliera, A. R., Manzotti, G., Cattelani, S., Candini, O., Grisendi, G., Vergalli, J., Mariani, S. A., et al. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24040 · Cited by 8
“AML1-ETO can also physically interact with C/EBPa blocking transcription of C/EBParegulated genes [Pabst et al., 2001].”
BackgroundAdvances in the molecular genetics of acute leukemia
Scandura, J. M. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0058-1 · Cited by 7
Epigenetic regulation of tumor suppressors in t(8:21)-containing AML
Yang, G., Khalaf, W. F., van de Locht, L. T., Jansen, J. H., van der Reijden, B. A., Müller‐Tidow, C., Delwel, R., Serve, H. L., Clapp, D. W., & Hiebert, S. W. (2004) · Annals of Hematology · doi:10.1007/s00277-003-0841-8 · Cited by 7
“This subgroup is characterized by mutations in C/EBPa as well as the t(8;21) [7, 8].”
BackgroundMyeloid leukemia factor 1: A “double-edged sword” in health and disease
Li, Z., Yang, Y., Wu, K., Li, Y., & Shi, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1124978 · Cited by 6
“Studies have shown that Trib1 and RUNX1-ETO downregulate C/EBPa and induce AML in mouse models (46, 47).”
BackgroundMutations in the runt homology domain of CBFα2 in myeloid malignancies with acquired trisomy 21
Snaddon, J., Neat, M. J., Fitzgibbon, J., Smith, M. L., Rohatiner, A. Z. S., Lister, T. A., & Amess, J. A. L. (2002) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(02)00525-3 · Cited by 6
Mouse Models of Human Blood Cancers: Basic Research and Pre-clinical Applications
Li, S. (2008) · Springer eBooks · doi:10.1007/978-0-387-69132-9 · Cited by 6
The Etiology of Acute Leukemia
Nichol, J. N., Assouline, S. E., & Miller, W. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_14 · Cited by 7
Moon, H., Shin, S., Kim, H. Y., Kim, Y. R., Cho, H. I., Yoon, S., Park, S. S., Kim, B. K., Chun, H., Kim, H., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404286 · Cited by 6
Hypoxia inducible factor-1alpha and leukemic cell differentiation.
Chen, G., Peng, Z.-G., Liu, W., Song, L., Jiang, Y., Huang, Y., & Zhao, Q. (2006) · PubMed · Cited by 6
Piazza, F., & Semenzato, G. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.3.387 · Cited by 6
C/EBPA methylation is common in T-ALL but not in M0 AML
Terriou, L., Abdelali, R. B., Roumier, C., Lhermitte, L., Vos, J. D., Cornillet‐Lefèbvre, P., Nibourel, O., Beldjord, K., Dombret, H., Leverger, G., et al. (2009) · Blood · doi:10.1182/blood-2008-09-176909 · Cited by 7
Zhang, Y., Wang, X.-L., Xu, C., Liu, N., Zhang, L., Zhang, Y., Xie, Y., Zhang, Y., Huang, Q., Wang, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.992714 · Cited by 8
“This cell line has been widely used for studying functions and mechanisms of many leukemogenic fusion proteins including AML1-ETO (Burel et al., 2001; Pabst et al., 2001; Alcalay et al., 2003), PML-RARα (Grignani et al.”
BackgroundZhang, M.-M., Liu, N., Zhang, Y.-L., Rong, B., Wang, X.-L., Xu, C., Xie, Y.-Y., Shen, S., Zhu, J., Nimer, S. D., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0398-8 · Cited by 5
Sudha, T., Godugu, K., Darwish, N. H. E., Tipu, N., & Mousa, S. A. (2021) · Cancers · doi:10.3390/cancers13164070 · Cited by 5
“The Kasumi-1 cell line is an intensively investigated model system of AML with t (8;21) translocation that results in a fusion protein (AML1-ETO), which plays an important role in the downregulation of CEBPA mRNA and protein and DNA binding activity, leading to great disturbance in granulocytic differentiation [24,25].”
BackgroundABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
Golovine, K. V., Abalakov, G., Lian, Z., Chatla, S., Karami, A. L., Chitrala, K. N., Madžo, J., Nieborowska-Skorska, M., Huang, J. Y., & Skórski, T. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00810-0 · Cited by 5
Robust Sample-Specific Stability Selection with Effective Error Control
Park, H., Yamada, M., Imoto, S., & Miyano, S. (2019) · Journal of Computational Biology · doi:10.1089/cmb.2018.0180 · Cited by 5
Wheat, J. C., & Steidl, U. G. (2021) · Blood · doi:10.1182/blood.2019004261 · Cited by 6
Transcriptional Regulation of Hematopoietic Stem Cells
Göttgens, B., & Green, A. R. (2004) · Elsevier eBooks · doi:10.1016/b978-012436643-5/50119-x · Cited by 5
Differentiation or leukemia: Is C/EBPα the answer?
Hiebert, S. W. (2001) · Nature Medicine · doi:10.1038/86461 · Cited by 7
CEBPA gene mutational status: a complete screening using high-resolution melt curve analysis.
Rázga, F., Dvořáková, D., Jurček, T., Ježíšková, I., Křístková, Z., & Mayer, J. (2009) · PubMed · doi:10.2165/01250444-200913030-00004 · Cited by 5
Delaney, C. S., & Bernstein, I. D. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04914.x · Cited by 5
“…with previous evidence of the leukaemic properties of the AML1-ETO fusion protein, namely down-regulation of C/EBPa in t(8;21) leukaemia cells (Pabst et al, 2001), a block of granulocytic differentiation, and anti-apoptotic properties (Klampfer et al, 1996; Westendorf et al, 1998; Kohzaki et…”
BackgroundZhang, X., Li, M., Chen, Y., Liu, J., Zhang, J., Shao, C., Deng, B., Zhang, J., Wang, T., Cao, J., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02698-0 · Cited by 4
“Results showed that shUSP6 led to signi fi cant upregulation of the myeloid differentiation marker (CD11b [27, 28]) in KASUMI-1 cells as well as the lymphoid differentiation marker (CD27 [29]) in REH cells, but did not induce obvious differentiation in the non-RUNX1-r cells (HL60, NB4, and OCI-AML3)…”
Haploinsufficient Transcription Factors in Myeloid Neoplasms
Martinez, T. C., & McNerney, M. E. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-013421 · Cited by 5
“Consequently, this translocation results in a neomorphic RUNX1 fusion protein that re-presses myeloid differentiation genes it normally activates, such as PU.1 , GATA1 , and CEBP (cid:11) (119–121).”
BackgroundKrum, E. A., Yamamoto, M., & Chauffaille, M. D. L. (2009) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802009000100006 · Cited by 4
“17,18 We found AML with t(8;21) in 14% of our patients and in one with FLT3/ITD + (2.5%).”
BackgroundInfluentialBarabino, S. M. L., Citterio, E., & Ronchi, A. E. (2021) · Cancers · doi:10.3390/cancers13153753 · Cited by 4
Kansal, R. (2021) · Journal of Hematology Research · doi:10.12974/2312-5411.2021.08.3 · Cited by 5
Chatzopoulou, M., Bonovolias, I. D., Nicolaou, I., Demopoulos, V. J., Vizirianakis, I. S., & Tsiftsoglou, A. S. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.041 · Cited by 4
Recent Applications of RNA Interference (RNAi) in Mammalian Systems
Scherer, L. J., & Rossi, J. J. (2007) · Springer eBooks · doi:10.1007/0-387-32956-0_8 · Cited by 4
AML1 and AML1 Fusion Protein AML1-ETO in Myeloid Gene Regulation and Leukemogenesis
Zhang, D., Burel, S. A., Zhou, L., Hetherington, C. J., & Yuan, Y. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2001.0391 · Cited by 5
Self-citationIntegrated Analysis Of Genetic And Epigenetic Alterations In Cancer
Toyota, M., Suzuki, H., Yamamoto, E., Yamano, H., Imai, K., & Shinomura, Y. (2009) · Epigenomics · doi:10.2217/epi.09.20 · Cited by 4
Schönherz, A. A., Bødker, J. S., Schmitz, A., Brøndum, R. F., Jakobsen, L. H., Roug, A. S., Severinsen, M. T., El‐Galaly, T. C., Jensen, P., Johnsen, H. E., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229593 · Cited by 4
CEBPA Gene Mutational Status: A Complete Screening Using High-Resolution Melt Curve Analysis
Rázga, F., Dvořáková, D., Jurřček, T., Ježíšková, I., Křístková, Z., & Mayer, J. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256325 · Cited by 6
The Etiology of Acute Leukemia
Nichol, J. N., Kinal, M., & Miller, W. H. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_12 · Cited by 4
Assem, M., Leithy, A. A. E., Hassan, N. M., Al-Karmalawy, A. A., Abozaid, M., Allam, R. M., Kamal, M., Amer, M., El-Sayyad, G. S., & Ibrahim, N. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-93024-2 · Cited by 3
Germline Predisposition in Hematologic Malignancies
Kansal, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00126-8 · Cited by 3
The t(8;21) fusion protein RUNX1-ETO downregulates PKM2 in acute myeloid leukemia cells
Yan, J., Li, Y.-D., Liu, S.-H., Yin, Q., Liu, X.-Y., Li, X., & Lu, Y. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272690 · Cited by 3
“role in leukemic transformation by blocking maturation and differentiation of myeloid progenitor cells [1,2].”
BackgroundTRIB2 regulates the differentiation of MLL–TET1 transduced myeloid progenitor cells
Kim, H., Oh, S. H., Kim, J.-H., Sohn, W., Kim, J., Kim, D.-H., Choi, S., Park, K. M., Ryoo, Z. Y., Park, T. S., et al. (2018) · Journal of Molecular Medicine · doi:10.1007/s00109-018-1700-3 · Cited by 3
Hassan, N. M., Said, F., Shafik, R. E., & Abdellateif, M. S. (2021) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-021-00154-z · Cited by 5
C/EBPα, do not forget your TIP60
So, C. W. E., & van der Reijden, B. A. (2008) · Leukemia · doi:10.1038/leu.2008.16 · Cited by 3
Genetic Alterations and Their Clinical Implications in Acute Myeloid Leukemia
Hou, H., Chou, W., & Tie, H.-F. (2011) · InTech eBooks · doi:10.5772/26421 · Cited by 5
In VivoChemical Screening for Modulators of Hematopoiesis and Hematological Diseases
Zhang, Y., & Yeh, J.-R. J. (2012) · Advances in Hematology · doi:10.1155/2012/851674 · Cited by 3
“A previous study had shown that AML1-ETO downregulates c/ebp α , resulting in a maturation block of the granulocytic cells in human t(8; 21) AML [122].”
New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins
Li, J., Guo, C. H., Steinauer, N., & Zhang, J. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1415-1 · Cited by 4
Molecular genetics of acute myeloid leukemia
Gruber, T. A., & Downing, J. R. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977633.009 · Cited by 3
Liu, Y., Liu, W. X., Mei, Y., Huang, Q., Liu, X., Guo, C., Chen, M., Mou, J., Wang, S., Xie, W., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70077 · Cited by 2
“4,6,7 Although high remission rates could be induced in most t(8;21) AML patients following standard treatment, about 40% of patients will experience relapse after achieving complete remission (CR).”
JAK-STAT pathway in hematological malignancies: Achievements, challenges and future perspectives
Pan, B., Shi, K., Li, Y., Wang, X., Song, C., Zhang, Q., & Li, L. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118959 · Cited by 5
Proteomics of AML1/ETO Target Proteins: AML1–ETO Targets a C/EBP–NM23 Pathway
Singh, S. M., Trivedi, A. K., Lochab, S., Christopeit, M., Hiddemann, W., & Behre, G. (2010) · Clinical Proteomics · doi:10.1007/s12014-010-9051-2 · Cited by 2
“AML1–ETO Upregulates NM23 by Blocking the Ability of CCAAT Enhancer Binding Proteins (C/EBP) to Downregulate the NM23 promoter NM23 and AML1–ETO are involved in a block of granulocytic differentiation [20, 39, 53], and C/EBPα induces granulocytic differentiation [54, 55].”
BackgroundSelf-citationWang, S., Liu, Y., Zhao, X., Wang, X., Lou, J., Jin, P., Zhang, Y., Yu, J., & Wang, K. (2024) · British Journal of Haematology · doi:10.1111/bjh.19565 · Cited by 2
Epigenetic Modifications Mediated by the AML1/ETO and MLL Leukemia Fusion Proteins
Duque‐Afonso, J., Lübbert, M., & Cleary, M. L. (2013) · Springer eBooks · doi:10.1007/978-3-642-38404-2_6 · Cited by 2
Staib, P., Lippl, S., & Spiekermann, K. (2015) · best practice onkologie · doi:10.1007/s11654-015-0247-9 · Cited by 4
Sampath, D. (2012) · Springer eBooks · doi:10.1007/978-94-007-4655-8_7 · Cited by 2
Monzen, S., Chiba, M., Ueno, T., Morino, Y., Terada, K., Yamaya, H., & Hosokawa, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8099 · Cited by 2
“CEBPA is essential for normal granulopoiesis, and the dominant-negative mutations of the CEBPA gene have been identified in a large proportion of the malignant cells from patients with myeloblastic subtypes of acute myeloid leukemia (13).”
Recent applications of RNA interference (RNAi) in mammalian systems
Scherer, L. J., & Rossi, J. J. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-004-4924-8 · Cited by 2
Tang, D., Hu, P., Zhu, D., Luo, Y., Chen, M., Zhang, G., & Wang, Y. (2021) · Aging · doi:10.18632/aging.203000 · Cited by 4
“In clinical samples, a report revealed that expression of C/EBPα in APL is lower than that of normal bone marrow [38], whereas others found that there were no significant differences in C/EBPα expression between APL and normal bone marrow samples [35, 39].”
BackgroundMechanism-based therapy for leukemia: a lesson from ATRA therapy.
Naoe, T. (2001) · PubMed · doi:10.18999/nagjms.64.3-4.103 · Cited by 2
Sabatier, M., Birsen, R., Lauture, L., Dehairs, J., Angelino, P., Mouche, S., Heiblig, M., Boët, E., Sahal, A., Saland, E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.15.488522 · Cited by 2
Genomic Landscape and Risk Stratification of Acute Myeloid Leukemia
Hou, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-3810-0_5 · Cited by 1
RNA activation of CEBPA improves leukemia treatment
Kovecses, O., Sharif-Askari, B., González‐Losada, C., Reebye, V., Ryan, B. M., Kwok, A., Habib, N., Luedtke, N. W., Mercier, F., & McKeague, M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102611 · Cited by 3
Elucidating the risk factors and oncogene drivers of acute myeloid leukemia
Sanya, D. R. A., & Onésime, D. (2025) · Human Cell · doi:10.1007/s13577-025-01294-9 · Cited by 1
Metadata
- Authors
- Pabst, T., Mueller, B. U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.-E., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Helmholtz Munich (DE)
- Scripps Research Institute (US)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Medicine
- Published
- 2001-04
- Volume
- 7
- Issue
- 4
- Pages
- 444-451
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1489323849
- Semantic Scholar
- 0dc02b7bfde7f6d2b964fdb5715593ac0bec54f2
- Cited by
- 463
- References
- 45
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 12 · 2022: 4 · 2021: 16 · 2020: 8 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 18 · 2012: 18
- FWCI
- 15.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- AML1-ETO, C/EBPα, CEBPA, acute myeloid leukemia, granulocytic differentiation, transcriptional repression, conditional gene expression, U937 cells, Kasumi-1 cells, therapeutic target
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Animals, Base Sequence, Cell Differentiation, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, DNA-Binding Proteins, Humans, Promoter Regions, Genetic, Proto-Oncogene Proteins, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Translocation, Genetic, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Down-Regulation, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.